幽门螺杆菌是大多数胃溃疡和部分消化系统癌症的原因。抗生素耐药株的出现和传播是其感染治疗中最重要的挑战之一。本研究旨在开发一种基于凝集素A（ConA）包被壳聚糖（CS）纳米载体的药物传递系统，以便将多肽定位释放至幽门螺杆菌感染部位。因此，使用壳聚糖作为CM11肽的包封剂，采用离子凝胶化方法进行传递。使用ConA来包覆CS纳米颗粒以定位幽门螺杆菌。采用傅里叶红外光谱、动态光散射（DLS）和扫描电子显微镜（SEM）对CS NPs和ConA-CS NPs进行了特性表征。在体外分析了CM11载荷的ConA-CS NPs对幽门螺杆菌SS1株的最小抑制浓度（MIC）。为了评估治疗效果，建立了小鼠幽门螺杆菌SS1株胃感染模型，并进行了组织病理学研究和IL-1β细胞因子分析。根据结果，CS NPs和ConA-CS NPs的尺寸频率分别约为200和350 nm。制备的CM11载荷的ConA-CS NPs对幽门螺杆菌SS1株表现出抗菌活性，浓度为32 µg/ml。合成的CM11载荷的ConA-CS NPs治疗方式显示出最好的愈合效果，并观察到IL-1β显著降低。我们的研究结果强调了壳聚糖纳米颗粒在治疗幽门螺杆菌SS1株胃感染模型中作为药物传递载体的潜力。© 2023. 作者。

Helicobacter pylori is the cause of most cases of stomach ulcers and also causes some digestive cancers. The emergence and spread of antibiotic-resistant strains of H. pylori is one of the most important challenges in the treatment of its infections. The present study aims to develop a concanavalin A (ConA) coated chitosan (CS) nanocarrier-based drug delivery for the targeted release of peptides to the site of H. pylori infection. Accordingly, chitosan was used as an encapsulating agent for CM11 peptide delivery by applying ionotropic gelation method. Con-A was used for coating CS nanoparticles to target H. pylori. The CS NPs and ConA-CS NPs were characterized by FTIR, dynamic light scattering (DLS), and scanning electron microscopy (SEM). The MIC of CM11-loaded ConA-CS NPs against H. pylori SS1 strain was analyzed in vitro. In order to evaluate the treatment efficiency in vivo, a gastric infection model of H. pylori SS1 strain was established in mice and histopathological studies and IL-1β cytokine assay were performed. Based on the results, the size frequency for CS NPs and ConA-CS NPs was about 200 and 350 nm, respectively. The prepared CM11-loaded ConA-CS NPs exhibited antibacterial activity against H. pylori SS1 strain with a concentration of 32 µg/ml. The highest healing process was observed in synthesized CM11-loaded ConA-CS NPs treatments and a significant decrease in IL-1β was observed. Our findings highlight the potential of chitosan nanoparticles as a drug delivery vehicle in the treatment of gastric infection model of H. pylori SS1 strain.© 2023. The Author(s).